<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990795</url>
  </required_header>
  <id_info>
    <org_study_id>CYCLO1</org_study_id>
    <nct_id>NCT00990795</nct_id>
  </id_info>
  <brief_title>Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery</brief_title>
  <acronym>CYCLO1</acronym>
  <official_title>A Randomized Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of cyclosporine has been found to have a myocardial protective effect,&#xD;
      improving post-operative cardiac function in patients undergoing percutaneous coronary&#xD;
      interventions by diminishing infarct size. The purpose of the proposed study is to conduct a&#xD;
      randomized, controlled clinical trial in patients undergoing isolated valvular heart surgery,&#xD;
      or coronary artery bypass surgery. Specifically the investigators will evaluate the&#xD;
      cardio-protective effects of cyclosporine on post ischemic-arrest myocardium. The two factors&#xD;
      will be treatment group and cyclosporine versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim of this study is to perform a randomized controlled study to compare the&#xD;
      effects of cyclosporine v. placebo on changes in myocardial functioning associated with open&#xD;
      heart surgery for isolated valvular or coronary artery bypass procedures.&#xD;
&#xD;
      The research question is:&#xD;
&#xD;
      Compared to placebo, does administration of cyclosporine just before surgery improve&#xD;
      myocardial functioning in terms of:&#xD;
&#xD;
        -  Transthoracic ECHO (TTE) assessment of ejection fraction&#xD;
&#xD;
        -  Cardiac index (CI), mixed venous oxygen saturation (SVO2), systemic vascular resistance&#xD;
           (SVR)&#xD;
&#xD;
        -  Length of stay&#xD;
&#xD;
        -  30-d mortality&#xD;
&#xD;
        -  Angina Scale&#xD;
&#xD;
        -  SF-36 measure of quality of life&#xD;
&#xD;
        -  Measures associated with myocardial function:&#xD;
&#xD;
             1. Cardiac Index&#xD;
&#xD;
             2. Blood glucose level&#xD;
&#xD;
             3. Serum Troponin I level&#xD;
&#xD;
             4. Free Fatty Acid levels&#xD;
&#xD;
             5. Serum CPK-MB levels&#xD;
&#xD;
             6. Serum phosphoratase levels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution.&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Stay (LOS)</measure>
    <time_frame>postoperative to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (TTE)</measure>
    <time_frame>postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVO2</measure>
    <time_frame>Postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance (SVR)</measure>
    <time_frame>postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Men and women, 18 years of age or older&#xD;
&#xD;
          -  Patients with multi-vessel coronary artery disease&#xD;
&#xD;
          -  Patients undergoing isolated valvular heart surgery (aortic/ mitral)&#xD;
&#xD;
          -  Patients undergoing CABG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac arrest&#xD;
&#xD;
          -  Patients with ventricular fibrillation&#xD;
&#xD;
          -  Patients with cardiogenic shock&#xD;
&#xD;
          -  Patients requiring circulatory arrest&#xD;
&#xD;
          -  Patients with known hypersensitivity to cyclosporine&#xD;
&#xD;
          -  Patients with known renal failure or a GFR &lt;50 ml/min/1.732&#xD;
&#xD;
          -  Patients with liver failure&#xD;
&#xD;
          -  Patients with uncontrolled hypertension&#xD;
&#xD;
          -  Women who are pregnant or who are of childbearing age and not on contraception&#xD;
&#xD;
          -  Patients with a serum bilirubin level greater than 3 mg/100 mL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon-Cecil M Walkes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical School Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heinrich Taegtmeyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas Medical School Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George K Goodrick, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Medical School Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical School Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jon-Cecil Walkes, MD</name_title>
    <organization>University of Texas Medical School Houston</organization>
  </responsible_party>
  <keyword>open heart surgery</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>myocardial protection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

